Markets
Markets
AI
Markets
AI
Ideas
AI
Danish biotech Genmab has seen its shares double in three months after a string of major cancer drug trial successes, giving fresh momentum to its push to take greater control of the medicines it develops and sells.
AI
AI
AI
World
Politics
AI
AI
AI
AI
Politics
Politics
AI
Markets
AI
Science
AI
Politics
World
Markets
Markets
Markets
AI
World
World
World
Politics
Politics
Politics
Business
Business
Business
Tech
Tech
Tech
Tech
Tech
Tech
Tech
Climate
Climate
Climate
Health
Health
Health
Politics
AI
AI
Health
Ideas
Markets
AI
AI
AI
AI
World
Ideas